Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
New findings from E. Campora and co-authors in the area of breast cancer published
March 5th, 2009
"Docetaxel is the most active agent for metastatic breast cancer, but the optimal treatment regimen as a single agent has yet to be defined. Two consecutive monocentric phase II trials of docetaxel in metastatic breast cancer were carried out," investigators in Imperia, Italy report. "In Trial I, 36 patients received docetaxel 35 mg/m(2) weekly for 6 weeks every 8 weeks and in Trial II, 29 patients received docetaxel 100 mg/m(2) day 1 every 21 days. Patient characteristics were comparable. However, patients with liver involvement comprised 25% of cases in Trial I and 55% in Trial H. The overall response rate on an intention-to-treat basis was 19% vs. 45% in Trial I and...
Source: Women's Health Weekly (2009-03-05)
|
